{"id":613548,"date":"2026-09-27T17:36:09","date_gmt":"2026-09-27T17:36:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/613548\/"},"modified":"2026-09-27T17:36:09","modified_gmt":"2026-09-27T17:36:09","slug":"one-crispr-treatment-cut-bad-cholesterol-in-half-for-a-full-year","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/613548\/","title":{"rendered":"One CRISPR treatment cut \u201cbad\u201d cholesterol in half for a full year"},"content":{"rendered":"<p id=\"first\">A first-in-human Phase 1 clinical trial from Cleveland Clinic found that a single infusion of a CRISPR-Cas9 gene-editing therapy produced lasting reductions in LDL (&#8220;bad&#8221;) cholesterol and triglycerides in people with lipid disorders that had not responded adequately to medications.<\/p>\n<p>The study followed 15 patients for one year to determine whether the cholesterol and triglyceride reductions <a href=\"http:\/\/newsroom.clevelandclinic.org\/2025\/11\/08\/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-lower-cholesterol-and-triglycerides\" rel=\"nofollow noopener\" target=\"_blank\">previously reported<\/a> after two months would continue over time. After 12 months, participants who received the highest dose had a 52.5% reduction from baseline in LDL cholesterol and a 47.8% drop in triglycerides.<\/p>\n<p>No serious adverse events related to the therapy were reported during the one-year follow-up.<\/p>\n<p>Cholesterol Reductions Lasted for a Year<\/p>\n<p>The findings were presented at the 2026 European Society of Cardiology annual meeting and published at the same time in the New England Journal of Medicine.<\/p>\n<p>&#8220;Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive,&#8221; said Cleveland Clinic cardiologist Luke Laffin, M.D., first author of the study.&#8221;It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.&#8221;<\/p>\n<p>CRISPR-Cas9 is a gene-editing technology designed to make targeted changes to specific parts of a person&#8217;s DNA. Researchers are studying it as a potential way to treat serious diseases by altering genes that contribute to those conditions.<\/p>\n<p>How CTX310 Targets Blood Fats<\/p>\n<p>The experimental treatment tested in the trial, called CTX310, is given as a one-time infusion. It carries the CRISPR editing system to the liver, where it switches off a gene known as ANGPTL3.<\/p>\n<p>ANGPTL3 helps regulate fats circulating in the blood. Disabling the gene can reduce LDL cholesterol and triglycerides, both of which are associated with cardiovascular disease.<\/p>\n<p>During the study, patients received CTX310 at doses ranging from 0.1 to 0.8 mg\/kg. Before the infusion, they were treated with corticosteroids and antihistamines.<\/p>\n<p>Researchers then monitored participants for treatment safety and measured changes in ANGPTL3, LDL cholesterol, and triglyceride levels.<\/p>\n<p>At the highest dose, CTX310 lowered both LDL cholesterol and triglycerides by about 50% on average 12 months after treatment.<\/p>\n<p>Long-Term Monitoring Will Continue<\/p>\n<p>Although the early results are encouraging, CTX310 remains experimental and the study involved only 15 people.<\/p>\n<p>Participants were monitored for one year after treatment, and researchers plan to continue long-term safety follow-up for another 15 years, in line with FDA recommendations for gene-editing therapies.<\/p>\n<p>The study was funded by CRISPR Therapeutics AG; Zug, Switzerland.<\/p>\n<p>Dr. Laffin&#8217;s institution has received research funding from Crispr Therapeutics.<\/p>\n","protected":false},"excerpt":{"rendered":"A first-in-human Phase 1 clinical trial from Cleveland Clinic found that a single infusion of a CRISPR-Cas9 gene-editing&hellip;\n","protected":false},"author":2,"featured_media":613549,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,302106,111,139,69],"class_list":["post-613548","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-liver-disease-cholesterol-personalized-medicine-alternative-medicine-diseases-and-conditions-gene-therapy-chronic-illness-genes","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/613548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=613548"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/613548\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/613549"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=613548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=613548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=613548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}